ADMA Biologics Inc (NASDAQ:ADMA) Sees Significant Decrease in Short Interest

Key Points

• Short interest fell 14.1% to 22,175,506 shares as of March 31, equal to 9.6% of shares sold short and a days-to-cover ratio of 1.6.
• Quarterly results met estimates: ADMA reported $0.20 EPS and $139.16 million in revenue (up 18.4% year-over-year), with strong profitability metrics including a 37.52% ROE and a 28.8% net margin.
• Analyst and ownership backdrop: the stock carries an average "Buy" rating with a consensus price target of $28.00, institutional investors own 75.68% of shares, and insiders recently both sold (COO) and bought (a director) stock.

ADMA Biologics Inc (NASDAQ:ADMA - Get Free Report) was the recipient of a significant decrease in short interest in the month of March. As of March 31st, there was short interest totaling 22,175,506 shares, a decrease of 14.1% from the March 15th total of 25,826,838 shares. Currently, 9.6% of the company's shares are sold short. Based on an average daily volume of 13,551,247 shares, the days-to-cover ratio is presently 1.6 days.

ADMA Biologics Stock Performance

Shares of ADMA stock opened at $10.74 on Friday. The stock has a fifty day moving average of $13.56 and a 200 day moving average of $15.82. ADMA Biologics has a 52 week low of $7.21 and a 52 week high of $25.67. The firm has a market capitalization of $2.56 billion, a price-to-earnings ratio of 17.90 and a beta of 0.82. The company has a quick ratio of 3.74, a current ratio of 6.71 and a debt-to-equity ratio of 0.16.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 EPS for the quarter, hitting analysts' consensus estimates of $0.20. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.The company had revenue of $139.16 million during the quarter, compared to analyst estimates of $139.80 million. During the same quarter last year, the firm posted $0.46 earnings per share. The firm's revenue was up 18.4% on a year-over-year basis. As a group, research analysts expect that ADMA Biologics will post 0.51 earnings per share for the current year.

Insider Buying and Selling

In other news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $15.63, for a total transaction of $157,800.48. Following the completion of the sale, the chief operating officer owned 466,600 shares of the company's stock, valued at approximately $7,292,958. This represents a 2.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Steve Elms acquired 7,000 shares of the company's stock in a transaction dated Thursday, March 5th. The shares were bought at an average cost of $15.67 per share, with a total value of $109,690.00. Following the purchase, the director owned 2,038,730 shares of the company's stock, valued at approximately $31,946,899.10. This trade represents a 0.34% increase in their position. The SEC filing for this purchase provides additional information. Corporate insiders own 3.50% of the company's stock.

Institutional Trading of ADMA Biologics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC lifted its stake in ADMA Biologics by 16.4% in the first quarter. SG Americas Securities LLC now owns 70,160 shares of the biotechnology company's stock worth $632,000 after acquiring an additional 9,908 shares during the period. Rockefeller Capital Management L.P. lifted its stake in ADMA Biologics by 60.7% in the fourth quarter. Rockefeller Capital Management L.P. now owns 4,485 shares of the biotechnology company's stock worth $82,000 after acquiring an additional 1,694 shares during the period. Corient Private Wealth LLC lifted its stake in ADMA Biologics by 58.0% in the fourth quarter. Corient Private Wealth LLC now owns 91,367 shares of the biotechnology company's stock worth $1,667,000 after acquiring an additional 33,541 shares during the period. Vident Advisory LLC lifted its stake in ADMA Biologics by 24.2% in the fourth quarter. Vident Advisory LLC now owns 270,492 shares of the biotechnology company's stock worth $4,934,000 after acquiring an additional 52,687 shares during the period. Finally, First Citizens Bank & Trust Co. raised its holdings in ADMA Biologics by 24.4% in the fourth quarter. First Citizens Bank & Trust Co. now owns 48,763 shares of the biotechnology company's stock worth $889,000 after purchasing an additional 9,576 shares in the last quarter. Hedge funds and other institutional investors own 75.68% of the company's stock.

Wall Street Analysts Forecast Growth

ADMA has been the subject of a number of analyst reports. Cantor Fitzgerald reissued a "neutral" rating on shares of ADMA Biologics in a research note on Thursday, March 26th. Mizuho dropped their price objective on ADMA Biologics from $30.00 to $24.00 and set an "outperform" rating for the company in a research note on Monday. Zacks Research raised ADMA Biologics from a "hold" rating to a "strong-buy" rating in a research note on Monday, March 2nd. Wall Street Zen raised ADMA Biologics from a "hold" rating to a "buy" rating in a research note on Saturday, February 28th. Finally, Weiss Ratings reissued a "hold (c)" rating on shares of ADMA Biologics in a research note on Tuesday, December 23rd. Two investment analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $28.00.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company's marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.